The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
暂无分享,去创建一个
E. Van Cutsem | L. Rubbia‐Brandt | J. Tabernero | J. Figueras | P. Rougier | G. Poston | E. Loyer | N. Kokudo | A. de Gramont | A. Sobrero | F. Kunstlinger | R. Adam | C. Teh | A. Guthrie | L. Rubbia-Brandt
[1] M. Piccart,et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Sundin,et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Myeong-Jin Kim,et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases , 2012, European Radiology.
[4] C. Köhne,et al. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. , 2012, Clinical colorectal cancer.
[5] M. Gönen,et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. , 2012, Surgery.
[6] F. Lévi,et al. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. , 2011, European journal of cancer.
[7] M. Gönen,et al. Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer , 2011, Annals of surgery.
[8] F. Zaccagna,et al. Liver Metastases From Colorectal Cancer Treated With Conventional and Antiangiogenetic Chemotherapy: Evaluation With Liver Computed Tomography Perfusion and Magnetic Resonance Diffusion-Weighted Imaging , 2011, Journal of computer assisted tomography.
[9] C. Dejong,et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[10] P. Low,et al. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance , 2011, Modern Pathology.
[11] T. Hickish,et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] T. Gruenberger,et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? , 2011, European journal of radiology.
[13] M. Ducreux,et al. Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome , 2011, Annals of surgery.
[14] D. Lambrechts,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.
[15] S. Bruin,et al. Molecular alterations associated with liver metastases development in colorectal cancer patients , 2011, British Journal of Cancer.
[16] M. Haider,et al. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Gruenberger,et al. Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including bevacizumab prior liver resection. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Salazar,et al. A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Choti,et al. Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis , 2011, Clinical Cancer Research.
[21] J. Gu,et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. , 2011, World journal of gastroenterology.
[22] S. Curley,et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Irène Buvat,et al. Detection and Characterization of Tumor Changes in 18F-FDG PET Patient Monitoring Using Parametric Imaging , 2011, The Journal of Nuclear Medicine.
[24] H. Sorbye,et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Stoker,et al. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. , 2010, Radiology.
[26] S. McLachlan,et al. Team dynamics, decision making, and attitudes toward multidisciplinary cancer meetings: health professionals' perspectives. , 2010, Journal of oncology practice.
[27] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Colombo,et al. Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.
[29] W. Oyen,et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases , 2010, Nuclear medicine communications.
[30] M. Mottolese,et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial , 2010, British Journal of Cancer.
[31] J. Vauthey,et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. , 2010, Clinical colorectal cancer.
[32] G. Fontanini,et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.
[33] Scott B Reeder,et al. Quantification of liver fat with magnetic resonance imaging. , 2010, Magnetic resonance imaging clinics of North America.
[34] Thomas M van Gulik,et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. , 2010, Radiology.
[35] S. Curley,et al. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.
[36] D. Sargent,et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. Curley,et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? , 2010, Journal of the American College of Surgeons.
[38] J. Vauthey,et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Ledermann,et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). , 2010 .
[40] A. Neville,et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[41] T. de Baère,et al. Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases , 2010, Annals of surgery.
[42] N. Petrelli,et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. , 2010, Journal of the National Cancer Institute. Monographs.
[43] Anna R Gagliardi,et al. Multidisciplinary cancer conferences: exploring obstacles and facilitators to their implementation. , 2010, Journal of oncology practice.
[44] E. Abdalla,et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis , 2010, Histopathology.
[45] R. J. Haas,et al. Impact of portal vein embolization on long‐term survival of patients with primarily unresectable colorectal liver metastases , 2010, The British journal of surgery.
[46] Massimo Midiri,et al. Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent , 2010, La radiologia medica.
[47] V. Torri,et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis , 2010, Journal of magnetic resonance imaging : JMRI.
[48] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[49] S. Curley,et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.
[50] F. Lévi,et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer , 2009, Cancer.
[51] E. Van Cutsem,et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial , 2009, British Journal of Cancer.
[52] D. Sargent,et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] H. Shimada,et al. Treatment for colorectal liver metastases: a review , 2009, Langenbeck's Archives of Surgery.
[54] W. Oyen,et al. Improved Selection of Patients for Hepatic Surgery of Colorectal Liver Metastases with 18F-FDG PET: A Randomized Study , 2009, Journal of Nuclear Medicine.
[55] A. Sundin,et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] D. Vriens,et al. Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review , 2009, Journal of Nuclear Medicine.
[57] M. Ducreux,et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] T. Conroy,et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] D. Grose,et al. Improving patient survival with the colorectal cancer multi‐disciplinary team , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[60] J. Vauthey,et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. , 2009, The Lancet. Oncology.
[61] E. Abdalla,et al. A Marking Technique for Intraoperative Localization of Small Liver Metastases Before Systemic Chemotherapy , 2009, Annals of Surgical Oncology.
[62] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] L. Rubbia‐Brandt,et al. Dangerous halo after neoadjuvant chemotherapy and two‐step hepatectomy for colorectal liver metastases , 2009, The British journal of surgery.
[64] H. Bismuth,et al. Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases , 2008, Annals of surgery.
[65] L. Ellis,et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] C Metcalfe,et al. Maximising recruitment into randomised controlled trials: the role of multidisciplinary cancer teams. , 2008, European journal of cancer.
[67] M. Choti,et al. Urgent need for a new staging system in advanced colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] T. Westin,et al. Tumour boards/multidisciplinary head and neck cancer meetings: are they of value to patients, treating staff or a political additional drain on healthcare resources? , 2008, Current opinion in otolaryngology & head and neck surgery.
[69] F. Lévi,et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[71] M. Ducreux,et al. Benefits of contrast-enhanced sonography for the detection of liver lesions: comparison with histologic findings. , 2008, AJR. American journal of roentgenology.
[72] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] P. Tekkis,et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.
[74] L. Ellis,et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.
[75] Yuman Fong,et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Georgia Salanti,et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. , 2007, The Lancet. Oncology.
[77] D. Lobo,et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study , 2007, Virchows Archiv.
[78] A. Carrato,et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.
[79] M. Choti,et al. Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional Analysis , 2007, Annals of Surgical Oncology.
[80] M. Ducreux,et al. Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin , 2007, Annals of Surgical Oncology.
[81] H. Reynolds,et al. Multidisciplinary teams in the management of rectal cancer. , 2007, Clinics in colon and rectal surgery.
[82] B. Siegel,et al. Chemotherapy-Induced Normalization of FDG Uptake by Colorectal Liver Metastases Does Not Usually Indicate Complete Pathologic Response , 2007, Journal of Gastrointestinal Surgery.
[83] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] S. Curley,et al. Comparison of CT methods for determining the fat content of the liver. , 2007, AJR. American journal of roentgenology.
[87] H. Petrowsky,et al. Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.
[88] F. Wright,et al. Multidisciplinary cancer conferences: a systematic review and development of practice standards. , 2007, European journal of cancer.
[89] T. Pawlik,et al. Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.
[90] S. Paterson-Brown,et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[91] Daniel Azoulay,et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] Susan Catt,et al. Multidisciplinary teams in cancer care: are they effective in the UK? , 2006, The Lancet. Oncology.
[93] L. Rubbia‐Brandt,et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[94] B. Thürlimann,et al. The multidisciplinary meeting: An indispensable aid to communication between different specialities. , 2006, European journal of cancer.
[95] M. Choti,et al. Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement , 2006, Annals of Surgical Oncology.
[96] M. Ychou,et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.
[97] N. Kemeny. Management of liver metastases from colorectal cancer. , 2006, Oncology.
[98] Catherine Julié,et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] P. Morel,et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.
[100] T. Crosby,et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[101] T. Pawlik,et al. Solitary colorectal liver metastasis: resection determines outcome. , 2006, Archives of surgery.
[102] T. Pawlik,et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] H. Bismuth,et al. Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. , 2006, HPB.
[104] Thomas Albrecht,et al. Potential Value of Contrast-Enhanced Intraoperative Ultrasonography During Partial Hepatectomy for Metastases: An Essential Investigation Before Resection? , 2006, Annals of surgery.
[105] P. Brown,et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] D. Sargent,et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] S. Curley,et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] L. Canedo,et al. Strategies to treat primary unresectable colorectal liver metastases. , 2005, Seminars in oncology.
[109] W. Leung,et al. Increasing incidence of colorectal cancer in Asia: implications for screening. , 2005, The Lancet. Oncology.
[110] C. McArdle,et al. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer , 2005, British Journal of Cancer.
[111] A. Zwinderman,et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. , 2005, Radiology.
[112] W. Hawkins,et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.
[113] P. Clavien,et al. Does the Novel PET/CT Imaging Modality Impact on the Treatment of Patients With Metastatic Colorectal Cancer of the Liver? , 2004, Annals of surgery.
[114] F. Lévi,et al. Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.
[115] P. Bachellier,et al. A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases , 2004, Annals of surgery.
[116] K. Vasiliadis,et al. Current treatment of colorectal liver metastases , 2004, Techniques in Coloproctology.
[117] M. Birchall,et al. Effect of process standards on survival of patients with head and neck cancer in the south and west of England , 2004, British Journal of Cancer.
[118] Bernard Paule,et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.
[119] I. Endo,et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. , 2004, Surgery.
[120] B. Rabinowitz. Interdisciplinary breast cancer care: declaring and improving the standard. , 2004, Oncology.
[121] F. Giuliante,et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[122] Kenneth Hess,et al. Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.
[123] L. Rubbia‐Brandt,et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] M. Ebell,et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. , 2004, The Journal of the American Board of Family Practice.
[125] L. Ellis,et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy , 2003, Journal of Gastrointestinal Surgery.
[126] P Garside,et al. Multidisciplinary team working, clinical networks, and chambers; opportunities to work differently in the NHS , 2003, Quality & safety in health care.
[127] H. Jefferies,et al. Multidisciplinary team working: is it both holistic and effective? , 2003, International Journal of Gynecologic Cancer.
[128] Robert C. G. Martin,et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. , 2003, Journal of the American College of Surgeons.
[129] B. Nordlinger,et al. Colorectal metastasis (liver and lung). , 2002, The Surgical clinics of North America.
[130] H. Bismuth,et al. Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors , 2000, Annals of surgery.
[131] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[132] L H Blumgart,et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.
[133] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[134] R. Reznek,et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. , 1998, British Journal of Cancer.
[135] S. Nathanson,et al. Multidisciplinary breast cancer clinics , 1997 .
[136] J. Faivre,et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer , 1995, The British journal of surgery.
[137] M. Ducreux,et al. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. , 1995, Journal of the American College of Surgeons.
[138] E. Watkins,et al. CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION. , 1964, The New England journal of medicine.
[139] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[141] Az Amsterdam,et al. Assessment of hepatic steatosis in patients undergoing liver resection:comparison of US,CT,T_1-weighted dualecho MR imaging, and point-resolved ~1H MR spectroscopy , 2010 .
[142] M. Eynde,et al. Treatment of colorectal liver metastases: a review. , 2009, Reviews on recent clinical trials.
[143] T. Conroy,et al. A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 ) , 2009 .
[144] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[145] M. Ducreux,et al. Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure , 2007, Annals of Surgical Oncology.
[146] T. Mok,et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases , 2005, Medical oncology.
[147] G. Fuhrman,et al. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. , 2000, Annals of surgery.
[148] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[149] K. Hughes. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases. , 1988, Surgery.
[150] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.